

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cutia Therapeutics**

**科笛集团**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2487)**

## **CHANGE OF NON-EXECUTIVE DIRECTOR**

### **RESIGNATION OF NON-EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Cutia Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Dr. Huang Xiao (“**Dr. Huang**”) has resigned as a non-executive director of the Company (“**Director**”) with effect from 30 December 2025 to focus more on his other personal commitment.

Dr. Huang has confirmed that he has no disagreement with the Board in any respect and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to thank Dr. Huang for his contributions to the Company during his tenure.

## APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is further pleased to announce that Mr. Lu Minfang (“**Mr. Lu**”) has been appointed as a non-executive Director with effect from 30 December 2025.

The biographical details of Mr. Lu are set out below:

Mr. Lu Minfang (盧敏放), aged 56, has been the partner of Yunfeng Investment Management (HK) Limited (“**Yunfeng**”) since June 2025. Prior to joining Yufeng, Mr. Lu has served as an executive director of China Mengniu Dairy Company Limited (中國蒙牛乳業有限公司\*), a company listed on the Stock Exchange (stock code: 2319), from September 2016 to October 2024, and as its chief executive officer from September 2016 to March 2024. Mr. Lu has been the chairman and a non-executive director of Yashili International Holdings Limited (雅士利國際控股有限公司) (Delisted, previous stock code: 1230), a company previously listed on the Stock Exchange and was privatised and delisted in 2023, from September 2016 to September 2023, and a non-independent director of Shanghai Milkground Food Tech Co., Ltd. (上海妙可藍多食品科技股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600882), from September 2021 to May 2024. Mr. Lu was a non-executive director of China Shengmu Organic Milk Limited (中國聖牧有機奶業有限公司), a company listed on the Stock Exchange (stock code: 1432), from July 2021 to May 2024. Mr Lu was also the chairman and a non-executive director of China Modern Dairy Holdings Ltd. (中國現代牧業控股有限公司), a company listed on the Stock Exchange (stock code: 1117), from March 2017 to February 2023. From February 2005 to September 2016, Mr. Lu served as vice president (Greater China) of Danone Early Life Nutrition Greater China, and worked at Danone S.A. and its subsidiaries and Dumex Baby Food Co., Ltd. From October 1995 to February 2005, Mr. Lu served at Johnson & Johnson (China) Company Limited as a marketing manager.

Mr. Lu is a global director of the Consumer Goods Forum (CGF) and a member of the Business Council of the World Economic Forum (WEF). Mr. Lu obtained his bachelor’s degree in biochemistry from Fudan University (復旦大學) in Shanghai in July 1991.

The Company has entered into a letter of appointment with Mr. Lu for an initial term of three years commencing from 30 December 2025, subject to retirement by rotation and re-election at the next annual general meeting of the Company pursuant to the articles of association of the Company. Such letter of appointment may be terminated by not less than 30 days’ notice in writing served by either the non-executive Director or the Company. Mr. Lu has agreed to act as a non-executive Director with no director’s fee.

Saved as disclosed above, to the best knowledge and belief of the Board and having made all reasonable enquiries and confirmed by Mr. Lu, as of the date of this announcement, Mr. Lu: (i) does not have, and is not deemed to have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571) of the Law of Hong Kong; (ii) does not hold any other positions in the Company or any of its subsidiaries; (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (“**Listing Rules**”)); (iv) has not held any directorships in other public companies of which are listed on any securities market in Hong Kong or overseas during the last three years; and (v) does not hold any other major appointments or professional qualifications.

Save as disclosed above, the Board is not aware of any other matters in relation to the appointment of Mr. Lu as a non-executive Director that need to be brought to the attention of the shareholders of the Company, nor is there any other information that should be disclosed by the Company pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Mr. Lu to the Board.

By order of the Board  
**Cutia Therapeutics**  
**Zhang Lele**  
*Chief Executive Officer and Executive Director*

Hong Kong, 30 December 2025

*As at the date of this announcement, the Board comprises (i) Ms. Zhang Lele and Mr. Huang Yuqing as executive directors; (ii) Dr. Chen Lian Yong, Dr. Xie Qin, Mr. Lu Minfang and Ms. Yang Yunxia as non-executive directors; and (iii) Mr. Chung Ming Kit, Mr. Zhang Zhisong and Mr. Ye Xiaoxiang as independent non-executive directors.*

\* *For identification purpose only*